

**PATENT**

**IN UNITED STATES PATENT AND TRADEMARK OFFICE**

Patent No.: 7,598,027

Docket No: 17596(BOT)

Issue Date: October 6, 2009

Patentee: Ester Fernandez-Salas et al.

Title            BOTULINUM TOXIN SCREENING ASSAYS

---

**REQUEST FOR CERTIFICATION OF CORRECTION**

Attn: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. We have also included the Issued Patent Proofing Form and a marked up version of the United States patent.

Pursuant to 1.20(a), the examiner is authorized to charge the Certificate of Correction fee of \$100.00 to the Deposit Account No.01-0885.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

The Examiner is authorized to charge any additional fees or credit overpayment to Deposit Account No. 01-0885.

Respectfully submitted,

**Customer Number: 51957**

**/Dean G. Stathakis/**

Date: November 3, 2009

By: Dean G. Stathakis

Reg. No.: 54,465

Telephone: 714-246-6521

Facsimile: 714-246-4249

Direct Correspondence to:  
Allergan, Inc.  
Legal Department-T2-7H  
2525 Dupont Drive  
Irvine, CA 92612

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,598,027

Page 1 of 2

APPLICATION NO.: 10/598,073

ISSUE DATE : October 6, 2009

INVENTOR(S) : Ester Fernandez-Salas et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 2, line 50, delete "HIT-T15" and insert -- HIT-T15 --, therefor.

In column 9-10, bottom of Table 6, line 12, delete "lung" and insert -- lung, --, therefor.

In column 12, line 12, delete "N-methylated" and insert -- N<sup>o</sup>-methylated --, therefor.

In column 22, line 21, delete "Control" and insert -- Control@ --, therefor.

In column 23, line 56, delete "tranfection," and insert -- transfection, --, therefor.

In column 28, line 9, delete "P" and insert --  $\beta$  --, therefor.

In column 29, line 35, delete "[125]" and insert -- [<sup>125</sup>I] --, therefor.

In column 30, line 35, delete "Cl" and insert -- C1 --, therefor.

In column 30, line 64-65, delete "Fernandez-Salas" and insert -- Fernandez-Salas --, therefor.

In column 32, line 16, after "2002)" insert -- . --.

In column 38, line 62, delete "Cl" and insert -- C1 --, therefor. In column 39, line 27, delete "Fernandez-Salas" and insert -- Fernandez-Salas --, therefor.

In column 40, line 39, delete "H<sub>c</sub>" and insert -- H<sub>C</sub> --, therefor.

MAILING ADDRESS OF SENDER:

Allergan, Inc.  
Attn: Dean G. Stathakis-T2-7H  
Legal Department  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. 7,598,027

Docket No: 17596(BOT)

No. of additional copies



**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO : 7,598,027

Page 2 of 2

APPLICATION NO.: 10/598,073

ISSUE DATE : October 6, 2009

INVENTOR(S) : Ester Fernandez-Salas et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 41, line 16, delete "Hc" and insert -- H<sub>C</sub> --, therefor.

In column 42, line 64, delete "(low glucise)" and insert -- (low glucose) --, therefor.

In column 43, line 54, delete "TWEEN-20," and insert -- TWEEN-20®, --, therefor.

In column 43, line 66, delete "TWEEN-20." and insert -- TWEEN-20®, --, therefor.

In column 45, line 38, delete "tranduction" and insert -- transduction --, therefor.

In column 51, line 15, delete "concentratin" and insert -- concentration --, therefor.

In column 53, line 7, delete "responsivness" and insert -- responsiveness --, therefor.

MAILING ADDRESS OF SENDER:

Allergan, Inc.  
Attn: Dean G. Stathakis-T2-7H  
Legal Department  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. 7,598,027

Docket No: 17596(BOT)

No. of additional copies

